Cannabinoid Agonist - Pipeline Insight, 2025

DelveInsight's, "Cannabinoid Agonist - Pipeline Insight, 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Cannabinoid Agonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered:

• Global coverage

Cannabinoid Agonist: Understanding

Cannabinoid Agonist: Overview

Cannabinoid agonists are compounds that activate the cannabinoid receptors (CB1 and CB2), which are part of the endocannabinoid system. These agonists can be natural (e.g., tetrahydrocannabinol or THC from cannabis), endogenous (e.g., anandamide), or synthetic (e.g., nabilone). They have diverse therapeutic applications, including pain management, appetite stimulation, anti-inflammatory effects, and neuroprotection. The increasing incidence of chronic pain, cancer, epilepsy, and neurodegenerative diseases has driven the demand for novel therapeutics, including cannabinoid agonists.

Cannabinoid agonists are compounds that activate cannabinoid receptors (CB1 and CB2) in the endocannabinoid system. Their structures typically feature terpene and phenolic components, which are characteristic of both phytocannabinoids (like THC and CBD) and synthetic cannabinoids (like dronabinol). Endogenous agonists, such as anandamide, have a fatty acid backbone with an amide group and long carbon chains. Phytocannabinoids, like THC, have a benzopyran ring fused with a terpene structure, while synthetic cannabinoids often include modified aromatic rings, providing unique receptor-binding properties. These structural features determine their ability to bind and activate cannabinoid receptors, influencing various physiological processes.

Cannabinoid agonists interact with the CB1 and CB2 receptors:

• CB1 Receptors: Primarily located in the brain and central nervous system, influencing mood, memory, pain perception, and appetite.
• CB2 Receptors: Found in immune cells and peripheral tissues, playing a role in inflammation and immune modulation.

Some cannabinoid agonists also influence non-cannabinoid targets, such as TRPV1 receptors and serotonin pathways, expanding their therapeutic potential.

Cannabinoid agonists have diverse therapeutic applications due to their interaction with the endocannabinoid system. They are widely used in pain management, particularly for chronic and neuropathic pain, and have shown efficacy in reducing inflammation in autoimmune diseases like rheumatoid arthritis. In neurological disorders, they help manage symptoms of epilepsy, multiple sclerosis, and Parkinson's disease. For mental health, they offer potential in treating anxiety, depression, and PTSD. In oncology, they assist with chemotherapy-induced nausea and vomiting and stimulate appetite in cancer and HIV/AIDS patients. Additionally, their neuroprotective properties are being explored for Alzheimer's disease and other neurodegenerative conditions.

"Cannabinoid Agonist - Pipeline Insight, 2025" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. A detailed picture of the Cannabinoid Agonist pipeline landscape is provided which includes the disease overview and Cannabinoid Agonist treatment guidelines. The assessment part of the report embraces, in depth Cannabinoid Agonist commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cannabinoid Agonist collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights:

• The companies and academics are working to assess challenges and seek opportunities that could influence Cannabinoid Agonist R&D. The therapies under development are focused on novel approaches to treat/improve Cannabinoid Agonist.

Cannabinoid Agonist Emerging Drugs Chapters

This segment of the Cannabinoid Agonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Cannabinoid Agonist Emerging Drugs

• AP-707: Apurano Pharmaceuticals

Adezunap (AP707) is an investigational THC-based cannabinoid formulation developed by Apurano Pharmaceuticals for chronic pain management. Utilizing the proprietary PuranoTec(R) manufacturing process, Adezunap is presented as an aqueous nanodispersion administered sublingually via a mouth spray, enhancing rapid and effective absorption through the oral mucosa. The formulation's small particle size (<250 nm) facilitates direct entry into the bloodstream, potentially offering a therapeutic alternative for the approximately 1.7 billion individuals worldwide suffering from chronic pain. Currently the drug is in Phase III stage of its development for the treatment of Chronic Pain.

• IGC-AD1: IGC Pharma, INC

IGC-AD1 is an investigational, proprietary cannabinoid-based product developed by India Globalization Capital (IGC). It is designed to be a CB2 receptor agonist aimed at treating Alzheimer's disease by modulating inflammation and neuroprotection in the brain. The product works by targeting the endocannabinoid system to help reduce the neuroinflammation associated with Alzheimer's. IGC-AD1 has shown promise in preclinical studies for improving cognitive function and addressing neurodegenerative processes, with ongoing clinical trials to evaluate its safety and efficacy. Currently, the drug is in the Phase II stage of its development for the treatment of Alzheimer Disease.

• NTRX 07: NeuroTherapia

NTRX-07 is an orally available small molecule that targets a key receptor on activated microglia, specialized cells that play an important role in regulating immune system activity in the CNS. The drug reduces inflammation and improves the brain's ability to form new connections, leading to improved learning and memory. Inflammation in the brain is increasingly recognized as an important factor in many neurological diseases, and NTRX-07 provides a new approach for the treatment of these challenging conditions. NeuroTherapia is initially developing this product for the treatment of Alzheimer's disease. Currently the drug is in Phase I stage of its development for the treatment of

Alzheimer's disease.

Cannabinoid Agonist: Therapeutic Assessment

This segment of the report provides insights about the different Cannabinoid Agonist drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Cannabinoid Agonist

There are approx. 20+ key companies which are developing the therapies for Cannabinoid Agonist. The companies which have their Cannabinoid Agonist drug candidates in the most advanced stage, i.e. Phase III include, Apurano Pharmaceuticals.

Phases

DelveInsight's report covers around 22+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Cannabinoid Agonist pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Cannabinoid Agonist: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cannabinoid Agonist therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cannabinoid Agonist drugs.

Cannabinoid Agonist Report Insights

• Cannabinoid Agonist Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Cannabinoid Agonist Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions:

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Cannabinoid Agonist drugs?
• How many Cannabinoid Agonist drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cannabinoid Agonist?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Cannabinoid Agonist therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Cannabinoid Agonist and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Apurano Pharmaceuticals
• IGC Pharma, Inc
• Artelo Biosciences, Inc
• NeuroTherapia
• Oxford Cannabinoid Technologies Holdings
• SciSparc
• Mira Pharmaceuticals
• InMed Pharmaceuticals
• Corbus Pharmaceuticals

Key Products

• AP-707
• IGC-AD1
• ART27.13
• NTRX 07
• OCT461201
• SCI 160
• MIRA-55
• INM 901
• CRB 913